Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Azad, Abul Kalam
Qiu, Xiaoping
Cuffe, Sinead
Qiu, Xin
Boyd, Kevin
Kuang, Qin
Emami, Marjan
Perera, Nicole
Palepu, Prakruthi R.
Patel, Devalben
Chen, Zhuo
Cheng, Dangxiao
Feld, Ronald
Leighl, Natasha B.
Shepherd, Frances A.
Tsao, Ming Sound
Xu, Wei
Liu, Geoffrey
机构：
[1] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada
[2] Wuhan Univ, Sch Med, Wuhan, Hubei, Peoples R China
[3] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[4] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1535
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Preoperative survivin, ERCC1, and PTEN expression in stage III non-small cell lung cancer (NSCLC) patients (pts) treated with neoadjuvant and definitive chemoradiation and association with overall survival (OS)
    Batus, Marta
    Fidler, Mary J.
    Walters, Kelly Kaiser
    Pool, Mark
    Mahon, Brett
    Basu, Sanjib
    Borgia, Jeffrey Allen
    Sher, David
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Preoperative Survivin, Ercc1 And Pten Expression In Stage III Non-small Cell Lung Cancer (nsclc) Patients(pts) Treated With Neoadjuvant And Definitive Chemoradiation And Association With Overall Survival (os).
    Batus, M.
    Fidler, M.
    Walters, K. Kaiser
    Pool, M.
    Mahon, B.
    Basu, S.
    Borgia, J. A.
    Sher, D.
    Bonomi, P. D.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S238 - S238
  • [43] Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy
    J. Nicholas Bodor
    Jessica R. Bauman
    Elizabeth A. Handorf
    Eric A. Ross
    Margie L. Clapper
    Joseph Treat
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1755 - 1763
  • [44] Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy
    Bodor, J. Nicholas
    Bauman, Jessica R.
    Handorf, Elizabeth A.
    Ross, Eric A.
    Clapper, Margie L.
    Treat, Joseph
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1755 - 1763
  • [45] OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Lynch, T. J., Jr.
    Neal, J.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Cuillerot, J.
    Reck, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 126 - 126
  • [46] Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.
    Lau, Sally C. M.
    Le, Lisa W.
    Chan, Sze Wah Samuel
    Smith, Elliot Charles
    Ryan, Malcolm
    Brown, M. Catherine
    Hueniken, Katrina
    Eng, Lawson
    Patel, Devalben
    Chen, RuiQi
    Zer, Alona
    Sung, Mike Ru
    Bradbury, Penelope Ann
    Ohashi, Pamela S.
    Shepherd, Frances A.
    Tsao, Ming Sound
    Leighl, Natasha B.
    Liu, Geoffrey
    Sacher, Adrian G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).
    Spigel, David R.
    Shum, Merrill Kingman
    Schneider, Jeffrey Gary
    Jotte, Robert M.
    Eisenstein, Jennifer L.
    Bhanderi, Viralkumar K.
    Konduri, Kartik
    Hung, Annie
    Hozak, Rebecca R.
    Ferry, David Raymond
    Gandhi, Leena
    Chao, Bo H.
    Rybkin, Igor I.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC).
    Randall, Megan
    Basu, Sanjib
    Batus, Marta
    Borgia, Jeffrey Allen
    Bonomi, Philip D.
    Fidler, Mary J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Correlation of PD-L1 expression with EGFR, KRAS, or ALK alterations and with survival of non-small cell lung cancer (NSCLC) treated with EGFR-TKIs: A meta-analysis of published trials.
    Li, Dianhe
    Zhu, Xiaoxia
    Li, Na
    Li, Yiyi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] The predictive role of integrated BRCA1 and HERC2 mRNA expression in advanced non-small cell lung cancer (NSCLC) patients (p) treated with platinum-based first-line chemotherapy
    Bonanno, Laura
    Costa, Carlota
    Javier Sanchez, Jose
    Majem, Margarita
    Gimenez Capitan, Ana
    Rodriguez, Ignacio
    Vergnenegre, Alain
    Massuti, Bartomeu
    Favaretto, Adolfo G.
    Rugge, Massimo
    Pallares, Cinta
    Taron, Miquel
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345